Αρχική World News Opinion: ‘Wales needs more than a three-page statement to get cancer services...

Opinion: ‘Wales needs more than a three-page statement to get cancer services back on track’

Wales A&E sign

At a time when cancer services in Wales have been severely disrupted due to the pandemic, the Welsh Government’s decision to publish just a short statement rather than a full cancer strategy on how it intends to provide and improve patient care over the next 5 years is unacceptable. Simply put, it’s failing cancer patients in Wales.

Cancer strategies matter. Just ask The World Health Organisation, which recommends that every nation should have one. Until the end of 2020, Wales had a Cancer Delivery Plan, which had ambitions for cancer care that matched the best in Europe. This strategy, which spanned 21 pages, has been replaced by a Quality Statement for Cancer that’s just 3 pages long.


Each year in Wales, around 19,300 people are diagnosed with cancer. Sadly, around 9,000 people die of the disease each year.

At Cancer Research UK, our ambition is that more people survive. To achieve this goal, we look to the Welsh Government to put effective measures in place to address some of the biggest problems facing cancer services. Transformation and problem-solving needs leadership and a strong foundation. This Quality Statement falls far short.

Together with the 20 other leading cancer charities who make up the Wales Cancer Alliance, we’re strongly urging the Welsh Government to change its approach and commit to a more comprehensive cancer strategy, like those seen elsewhere.

England and Scotland already have cancer plans in place, and we hope to see a new strategy launched in Northern Ireland this year. Wales could soon be the only UK nation without a cancer strategy.

Innovations and improvements for cancer patients

What we’re calling for goes deeper than replacing one plan with the next, just for the sake of having one. Far from an abstract concept, a cancer strategy is an incredibly important document that, when effective, can lead to demonstrable improvements for cancer patients.

It can help to drive change in how cancer services operate, leading to innovations that simply would not happen without the authority that a cancer strategy can bring and bringing us in line with other, better performing countries.

Take the Single Cancer Pathway, an innovation that can be directly linked to the now expired Cancer Deliver Plan. A UK first, it was introduced in 2019 and creates a more ambitious way of tracking every cancer diagnosis in Wales. With the help of a new cancer strategy, the Single Cancer Pathway could be the driver for a transformation in early diagnosis.

Rapid diagnostic clinics were piloted as a result of the Plan and these are now being rolled out across Wales for patients with non-specific but concerning symptoms that could be cancer.

Setting ambitious targets, tracking progress, embedding strong leadership, and supporting collaboration between government, clinicians, third sector organisations and patients, as well as much needed investment for staff, equipment and infrastructure, all these elements are missing from the Welsh Government’s Quality Statement for Cancer.

And if there’s ever been a time for strong leadership and a clear direction, it’s now.

Tackling the backlog of people waiting for a cancer diagnosis

Over the last year, cancer services have been heavily disrupted by the COVID-19 pandemic. We estimate that around 1,800 fewer people started cancer treatment in Wales from April to December 2020, compared to the same period in 2019, with some of the largest drops in breast, urological, lower GI and lung cancers. We need a strategy to outline how this significant backlog in cancer diagnoses and treatment will be tackled as quickly and safely as possible.

Today, the Welsh Government has also announced an NHS Recovery Plan, along with £100m to fund it. While it includes sections on cancer and diagnostics, there remains a lack of detail about exactly how services can recover. And so, the establishment of a comprehensive cancer strategy has become even more important as we emerge from the pandemic. This was a point raised by the Welsh Parliament/Senedd Cymru Cross Party Group on Cancer in its report in November 2020. A new cancer strategy for Wales was its first recommendation.

The path to recovery

Essentially, the Quality Statement represents a missed opportunity to address the biggest issues facing cancer diagnosis and care. For example, it says nothing about how shortages among staff who run scans and tests to detect cancer will be tackled, something which will hold back progress and stall clearing the backlog of people waiting for a diagnosis. It’s also uncertain how local health boards will be held to account on their performance by a document so light in detail.

Right now, we need to see a bold and ambitious vision, where we can see the path to recovery from the pandemic, where cancer services for people in Wales are improved in the long term and ultimately lives are saved. Simply, this document is not good enough.

Andy Glyde is a senior external affairs manager at Cancer Research UK

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women Under 40

U.S. breast cancer death rates decreased by about 1% per year between 2013 and 2018. What were the new case rates during that same...

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

A large, observational, registry-based study that leveraged systematically collected data gathered both retrospectively and prospectively through the International Replication Repair Deficiency Consortium reveals impressive...

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...